Tesamorelin

Typical use cases

Dosing guidelines

Titration

The approved label uses a fixed daily dose with no titration schedule; community protocols sometimes describe starting at a lower fraction of the daily dose and building up to reduce initial fluid-retention and joint discomfort, but this is not an approved practice.

Reconstitution

Lyophilized powder reconstituted with the supplied Sterile Water for Injection (Egrifta SV: one 2 mg vial with 0.5 mL diluent, yielding 1.4 mg/0.35 mL; original Egrifta: per kit instructions). Roll the vial gently for ~30 seconds to dissolve; do not shake. Use only if clear and colorless; administer immediately after reconstitution and discard any unused solution.

Injection sites

Subcutaneous injection into the abdomen, rotating sites with each dose and avoiding the navel, scar tissue, and bruised areas.

Storage & handling

Store the original unreconstituted vials at room temperature, 20-25C (68-77F), excursions permitted 15-30C (59-86F); keep in the original carton to protect from light. Do not freeze or refrigerate the reconstituted solution, which is intended for immediate use.

Side effects

• Injection-site reactions (erythema, pruritus, pain, irritation) Mild · Common
• Arthralgia and joint stiffness Mild · Common
• Peripheral edema and fluid retention Mild · Uncommon
• Myalgia and pain in extremity Mild · Uncommon
• Glucose intolerance / worsened glycemic control (elevated HbA1c) Moderate · Uncommon
• Hypersensitivity reaction (rash, urticaria, possible anaphylaxis) Severe · Rare

Research summary

Tesamorelin (Egrifta/Egrifta SV) is among the most rigorously studied growth-hormone-axis peptides, with FDA approval in 2010 based on two large 26-week phase 3 randomized, double-blind, placebo-controlled trials (LIPO-010, N=412; CTR-1011, N=404) in HIV patients with antiretroviral-associated lipodystrophy. In those trials it reduced visceral adipose tissue (VAT) by roughly 15-18% versus less than 5% with placebo, while sparing subcutaneous fat; benefit was maintained through 52 weeks in continuing patients and VAT reaccumulated after discontinuation. Mechanistically, the trans-3-hexenoic acid cap on the N-terminal tyrosine protects the GHRH backbone from DPP-4 cleavage, producing a more stable molecule that binds pituitary GHRH receptors and restores a more physiologic pulsatile GH/IGF-1 pattern rather than supplying exogenous GH. Beyond lipodystrophy, randomized trials by Stanley and colleagues (JAMA 2014; Lancet HIV 2019) showed tesamorelin reduced hepatic fat fraction by about 37% relative and reduced the proportion of patients with fibrosis progression in HIV-associated NAFLD, and there is exploratory interest in cognition and general metabolic/anti-aging use that remains largely off-label and less rigorously studied. Key limitations: nearly all controlled human data are in HIV-positive populations rather than the general or athletic populations where it is used in community settings; IGF-1 rises (a notable fraction of patients exceeded +3 SD), and modest worsening of glucose tolerance was observed in some trials. The evidence base is therefore strong for VAT/liver-fat endpoints in HIV but thinner for the broader longevity, body-composition, and cognitive claims often attached to it.

Key references

• https://www.ncbi.nlm.nih.gov/books/NBK548730/
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
• https://pubmed.ncbi.nlm.nih.gov/18057338/
• https://jamanetwork.com/journals/jama/fullarticle/1889139
• https://pmc.ncbi.nlm.nih.gov/articles/PMC6981288/
• https://pubmed.ncbi.nlm.nih.gov/22050344/

Related compounds